U.S. markets closed

Saniona AB (publ) (SANION.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
Add to watchlist
20.00-0.10 (-0.50%)
As of 12:23PM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close20.10
Open20.10
Bid19.90 x 0
Ask20.05 x 0
Day's Range19.70 - 20.20
52 Week Range15.00 - 44.50
Volume27,402
Avg. Volume165,544
Market Cap1.247B
Beta (5Y Monthly)1.01
PE Ratio (TTM)N/A
EPS (TTM)-3.74
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est77.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Saniona to present at three upcoming investor conferences
      GlobeNewswire

      Saniona to present at three upcoming investor conferences

      PRESS RELEASEJanuary 7, 2021Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that Rami Levin, President and Chief Executive Officer of Saniona, will present in the following three upcoming virtual investor conferences: 10th Annual LifeSci Partners Corporate Access Event Date: Thursday, January 7, 2021 Time: 11:30 a.m. Eastern Time Presentation and 1x1 Meetings Webcast Link: https://wsw.com/webcast/lifesci/sanion.st/2860611Biotech Showcase Date: Monday, January 11 – Friday, January 15, 2021 Time: On demand Presentation and 1x1 Meetings Webcast Link: https://informaconnect.com/biotech-showcase/digital-experience/BIO CEO and Investor Digital Conference Date: Tuesday, February 16 – Thursday, February 18, 2021 Time: On demand Presentation and 1x1 Meetings Webcast Link: https://www.bio.org/events/bio-ceo-investor-digital-conference/sessions?sessionTypes=25671   As available, these events will be made accessible and archived for approximately 90 days on the Saniona website in the Company Presentations section: https://saniona.com/investors/company-presentations/.For more information, please contact Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.comThe information was submitted for publication, through the agency of the contact person set out above, at 14:00 CET on January 7, 2021.About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.Attachment * Winter Conference Press Release 01.07.2021 (UK)

    • Saniona Appoints Chief Legal Officer and Chief Technical Operations Officer to Its Executive Team
      GlobeNewswire

      Saniona Appoints Chief Legal Officer and Chief Technical Operations Officer to Its Executive Team

      PRESS RELEASEDecember 21, 2020Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the further expansion of its executive team with the appointments of Denelle Waynick as Chief Legal Officer and Kyle Haraldsen as Chief Technical Operations Officer. The positions will be based in the U.S. and will support Saniona’s advancement of clinical trials for Tesomet and SAN711 as well as the company’s growing U.S. presence. “This has been a year of transformation for Saniona, evolving from a company focused on early-stage research to one capable of conducting its own mid-stage clinical trials. As we close out 2020, the hiring of Denelle and Kyle completes Saniona’s executive team in support of our current business,” said Rami Levin, President and CEO of Saniona. “As we look to 2021, our entire organization is focused on initiating Phase 2b clinical trials of Tesomet in HO and PWS, as well as advancing SAN711, the first drug candidate from our library of more than 20,000 proprietary ion channel modulators, into the clinic.”Denelle Waynick, Chief Legal Officer, has nearly 30 years of experience advising domestic and international companies in the healthcare and life sciences industries. Most recently, Waynick served as Chief Legal Officer and Corporate Secretary at MyoKardia, where she provided strategic and practical counsel to C-suite executives in legal matters, as well as issues impacted by the regulatory and policy environment. Waynick has also worked as in-house corporate counsel at UCB, Actavis and Schering-Plough, and in corporate law as an Associate and Partner at national and regional law firms. In addition to expertise in corporate, policy, governance and litigation matters, she has served as counsel on a range of global business transactions, including mergers, acquisitions and divestments. Waynick holds a B.S. in Accounting from Rutgers, the State University of New Jersey-Newark, and a JD from Howard University School of Law.“Saniona is a company uniquely positioned for long-term success — with both a mid-stage product in clinical development and a robust research engine to further its pipeline. I am excited about joining the team and contributing to Saniona’s robust growth,” said Waynick.Kyle Haraldsen, Chief Technical Operations Officer, has nearly 20 years of technical operations and manufacturing experience in the biopharmaceutical industry, including in support of U.S. and E.U. product approvals. Most recently, he served as the Vice President of Technical Operations and Project Management at AMAG Pharmaceuticals, where he led the process and analytical development, manufacturing, supply chain and project management functions. During his time at AMAG, Haraldsen oversaw multiple product launches, line extensions and the integration of two development stage assets. Prior to his time at AMAG, he was the Senior Director of Manufacturing at Radius Health, where he was responsible for the developmental, operational, and budgetary oversight of CMC programs and clinical trial material in support of global Phase 3 and multinational Phase 2 clinical trials. Haraldsen also worked for contract manufacturers Avecia Biotechnology and Johnson Matthey Pharma Services. He holds a B.S. in Chemical Engineering from Northeastern University.“As Saniona prepares to execute significant clinical trial programs, it will be essential that we have a strong technical operations function to oversee the manufacturing and supply of product in line with clinical development activities and timelines. I am eager to ensure we have the people and processes in place to support successful execution of our clinical programs, and to begin planning pre-commercial manufacturing and supply chain strategy,” said Haraldsen.Waynick and Haraldsen will serve on Saniona’s executive committee and will report to President and CEO Rami Levin. Both positions will be based in Saniona’s office in the Boston, Massachusetts-area, U.S. Waynick and Haraldsen will start in January 2021.For more information, please contactTrista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.comThe information was submitted for publication, through the agency of the contact person set out above, at 14:00 CET on December 21, 2020.About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com. Attachment * Dec New Hires Press Release 12.21.20 (UK)

    • Saniona was informed today that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%
      GlobeNewswire

      Saniona was informed today that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%

      PRESS RELEASEDecember 17, 2020Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it was informed that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%. The financial impact of this potential acquisition to Saniona is not known at this time. Novartis and Cadent each announced today that Novartis intends to acquire all of the outstanding capital stock of Cadent. Upon the closing of the transaction, Cadent will receive a $210 million upfront payment and will be eligible for up to $560 million in milestone payments, for a total potential consideration of $770 million. Saniona holds an ownership stake of approximately 3% in Cadent resulting from Cadent’s previous acquisition of the Saniona spin-out Ataxion, which was created to leverage Saniona’s ion channel expertise for the treatment of movement disorders.The financial impact of this potential acquisition to Saniona is not known at this time. Additional information will be provided upon receipt. The transaction between Cadent and Novartis is expected to close during the first quarter of 2021, subject to customary closing conditions, including antitrust review pursuant to the Hart-Scott-Rodino premerger notification program in the United States.In connection with Saniona’s existing agreement with Cadent, Saniona is also entitled to receive royalties on any potential products developed and commercialized from the SK ion channel program that originated with Ataxion, including the Phase 2 asset CAD-1883.Saniona has been a pioneer in the field of ion channels since its founding in 2011, and several members of the Saniona scientific team have been working in this field for more than 20 years. Since its inception, Saniona has out-licensed or spun-out multiple ion channel programs that are not aligned with its strategic focus on rare diseases. Ataxion was established in 2013 by Saniona and Atlas Venture Inc. with the aim of developing Saniona's research on SK ion channels (small conductance, calcium-activated potassium ion channels) for movement disorders. In 2017, Ataxion was acquired by Luc Therapeutics, which later changed its name to Cadent Therapeutics. The SK ion channel program produced CAD-1883, a first-in-class selective positive allosteric modulator of SK ion channels that Cadent has advanced into Phase 2 clinical trials and which may have potential in movement disorders. For more information, please contactTrista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.comThis information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 22:15 CET on December 17, 2020.About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.Attachment * Cadent.Novartis.Overview Press Release 12.17.20 (UK)